Generic Ximino Availability
Last updated on Jan 11, 2023.
Ximino is a brand name of minocycline, approved by the FDA in the following formulation(s):
XIMINO (minocycline hydrochloride - capsule, extended release;oral)
-
Manufacturer: JOURNEY
Approval date: July 11, 2012
Strength(s): EQ 45MG BASE, EQ 67.5MG BASE (discontinued), EQ 90MG BASE, EQ 112.5MG BASE (discontinued), EQ 135MG BASE
Has a generic version of Ximino been approved?
No. There is currently no therapeutically equivalent version of Ximino available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ximino. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Minocycline oral dosage forms for the treatment of acne
Patent 7,541,347
Issued: June 2, 2009
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical CoroprationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- April 2, 2027✓
- April 2, 2027
-
Minocycline oral dosage forms for the treatment of acne
Patent 7,544,373
Issued: June 9, 2009
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical CorporationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- April 2, 2027✓
- April 2, 2027
-
Minocycline oral dosage forms for the treatment of acne
Patent 7,790,705
Issued: September 7, 2010
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical CorporationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- June 24, 2025✓
- June 24, 2025
-
Method for the treatment of acne
Patent 7,919,483
Issued: April 5, 2011
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical CorporationA method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
Patent expiration dates:
- March 7, 2027✓
- March 7, 2027
-
Minocycline oral dosage forms for the treatment of acne
Patent 8,252,776
Issued: August 28, 2012
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical CorporationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- June 24, 2025✓
- June 24, 2025
-
Minocycline oral dosage forms for the treatment of acne
Patent 8,268,804
Issued: September 18, 2012
Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
Assignee(s): Medicis Pharmaceutical CorporationMinocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Patent expiration dates:
- June 24, 2025✓
- June 24, 2025
More about Ximino (minocycline)
- Check interactions
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: tetracyclines
- Breastfeeding
- En español
Patient resources
Other brands
Minocin, Solodyn, Dynacin, Minolira, Myrac
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.